Since 2017, eight new drugs have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of AML, including the FLT3 inhibitors midostaurin and gilteritinib, the IDH inhibitors ivosidenib and enasidenib, the anti-CD33 monoclonal antibody gemtuzumab ozogamicin, liposomal daunorubicin and cytarabine (CPX-351), the hedgehog pathway inhibitor glasdegib and the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax (10–19). Here, IDH1 is linked to acute myeloid leukemia.